Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 14, Issue 2, 2004, Pages 81-87

  Liu, M L ^a   James, R W ^b   Ylitalo, K ^a   Taskinen, M R ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Familial combined hyperlipoproteinemia; Free radicals; Gene polymorphism; Lipid peroxidation; Paraoxonase

Indexed keywords

ALKADIENE; APOLIPOPROTEIN A1; ARYLESTERASE; ENZYME; HIGH DENSITY LIPOPROTEIN; PARAOXONASE 1; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; CASE REPORT; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; FAMILIAL HYPERLIPEMIA; GENOTYPE; HUMAN; IN VITRO STUDY; KINETICS; MALE; MULTIVARIATE ANALYSIS; OXIDATION;

EID: 3042638495     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(04)80014-0     Document Type: Article

References (27)

1. Stein O, Stein Y (1999) Atheroprotective mechanisms of HDL. Atherosclerosis 144: 285-301
2. Shah PK, Kaul S, Nilsson J, Cercek B (2001) Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104: 2376-2383
3. Mackness MI, Harty D, Bhatnagar D, et al (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193-199
4. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21: 473-480
5. Ruiz J, Blanche H, James RW, et al (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346: 869-872
6. Raveh O, Pinchuk I, Schnitzer E, Fainaru M, Schaffer Z, Lichtenberg D (2000) Kinetic analysis of copper-induced peroxidation of HDL, autoaccelerated and tocopherol-mediated peroxidation. Free Radic Biol Med 29: 131-146
7. Francis GA (2000) High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 1483: 217-235
8. Navab M, Berliner JA, Subbanagounder G, et al (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21: 481-488
9. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590
10. Sanguinetti SM, Brites FD, Fasulo V, et al (2001) HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Diab Nutr Metab 14: 27-36
11. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52: 1544-1568
12. Porkka KV, Nuotio I, Pajukanta P, et al (1997) Phenotype expression in familial combined hyperlipidemia. Atherosclerosis 133: 245-253
13. Tilly-Kiesi M, Zhang Q, Ehnholm S, et al (1995) ApoA-IHelsinki (Lys107→0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol 15: 1294-1306
14. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res.Commun. 6: 67-75
15. Blatter Garin MC, Abbott C, Messmer S, et al (1994) Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 304: 549-554
16. Garin MC, James RW, Dussoix P, et al (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66
17. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki Jarvinen H (1988) Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8: 168-177
18. Havel JR, Eder HA, Bragdon JH (1955) Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353
19. James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101: 2252-2257
20. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW (2001) Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155: 229-235
21. Aviram M, Billecke S, Sorenson R, et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 118: 1617-1624
22. Cao H, Girard-Globa A, Berthezene F, Moulin P (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→ R genetic polymorphism. J Lipid Res 40: 133-139
23. Ludwig PW, Hunninghake DB, Hoidal JR (1982) Increased leucocyte oxidative metabolism in hyperlipoproteinaemia. Lancet 2: 348-350
24. Pronai L, Hiramatsu K, Saigusa Y, Nakazawa H (1991) Low superoxide scavenging activity associated with enhanced superoxide generation by monocytes from male hypertriglyceridemia with and without diabetes. Atherosclerosis 90: 39-47
25. Liu ML, Ylitalo K, Vakkilainen J, et al (2002) Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Ann Med 34: 48-54
26. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423: 57-60
27. Mackness MI, Arrol S, Mackness B, Durrington PN (1997) Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 349: 851-852